SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TheraTech (THRT)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Robert A. Gleason who wrote (35)3/10/1997 2:43:00 AM
From: Rick Strange   of 125
 
Robert,
I just established a position in THRT this last week. I had been waiting for a pull back from the euphoria of the Lilly partnership announced Jan 14th.

THRTs' transmucosal delivery system has already demonstrated its feasibility in Phase I/II clinical trials of GLP-1. Peptide drugs can currently only be delivered by injection since they are distroyed in the digestive system. Lilly markets many peptide drugs, such as insulin, heparin and growth harmones. The deal calls for Lilly to fund the development of up to six peptide drugs. The specific financial details haven't been disclosed yet.

Also on the positive side is Procter & Gambles' roll-out of Alora, the esrogen patch. THRT's once a day testosterone patch should also generate income this from U.S. sales to add to the income generated abroad.

For a biotech currently generating a profit, with a strong pipeline and substantial corporate partners, it is substantially undervalued at current prices.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News